Today: May 26, 2024
December 21, 2023
1 min read

Boyd Street Ventures backs game-changer, Cadenza Bio’s biotech breakthrough!

Boyd Street Ventures has announced an investment in biotech company Cadenza Bio. The company focuses on developing small molecules for demyelinating and inflammatory diseases, with a specific focus on multiple sclerosis (MS). Cadenza Bio aims to halt the progression of MS, restore function, and improve the quality of life for patients. The company holds an exclusive license to technology developed through a research collaboration between Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign and Dr. Seema Tiwari-Woodruff of the University of California, Riverside. Boyd Street Ventures is impressed with the potential of Cadenza Bio and believes that their participation will play a meaningful role in the company’s growth and development.

Previous Story

The life sciences champions: Top 5 mighty venture capital movers!

Next Story

Venture group secures colossal $389M fund, championing schizophrenia and vaccines!

Latest from Blog

Go toTop